Questcor Pharmaceuticals Inc Watch

from 8-K/A 1 page Exhibit Index

from 8-K 7 pages December 7, 2006 Questcor Pharmaceuticals, Inc. 3260 Whipple Road Union City, California, 94587 Ladies and Gentlemen: The Undersigned Entities Set Forth on Schedule I Hereto (Each an “Investor”), Hereby Confirm and Agree With You as Follows: 1. This Purchase Agreement (The “Agreement”) Is Made as the Date Hereof Between Questcor Pharmaceuticals, a California Corporation (The “Company”), and Each Investor That Is a Signatory to This Agreement

from 8-K 27 pages Questcor Pharmaceuticals, Inc. 11,400,000 Shares of Common Stock, No Par Value Per Share Placement Agency Agreement

from 10-Q 1 page [Article] 5 [Legend] This Schedule Contains Summary Financial Information Extracted From the Form 10-Q for the Period Ended January 31, 1999 and Is Qualified in Its Entirety by Reference to Such Financial Statements. [/Legend] <table> <s> <c> [Period-Type] 6-Mos [Fiscal-Year-End] Jul-31-1999 [Period-End] Jan-31-1999 [Cash] 2,937,680 [Securities] 7,591,806 [Receivables] 429,893 [Allowances] 0 [Inventory] 171,130 [Current-Assets] 179,552 [PP&E] 2,070,118 [Depreciation] (975,878) [Total-Assets] 16,562,746 [Current-Liabilities] 670,839 [Bonds] 199,036 [Preferred-Mandatory] 0 [Preferred] 0 [Common] 41,458,734 [Other-Se] (25,891,227) [Total-Liability-And-Equity] 16,562,746 [Sales] 1,247,055 [Total-Revenues] 1,247,055 [Cgs] 354,754 [Total-Costs] 4,387,078 [Other-Expenses] 66,373 [Loss-Provision] 0 [Interest-Expense] 20,191 [Income-Pretax] (3,092,056) [Income-Tax] 0 [Income-Continuing] (3,092,056) [Discontinued] 0 [Extraordinary] 0 [Changes] 0 [Net-Income] (3,092,056) [EPS-Primary] (0.20) [EPS-Diluted] (0.20) </Table>

from 10-Q 1 page [Article] 5 [Legend] This Schedule Contains Summary Financial Information Extracted From the Form 10q for the Period Ended April 30, 1998 and Is Qualified to Its Entirety by Reference to Such Financial Statements [/Legend] <table> <s> <c> [Period-Type] 9-Mos [Fiscal-Year-End] Jul-31-1998 [Period-End] Apr-30-1998 [Cash] 3,698,556 [Securities] 10,767,962 [Receivables] 378,473 [Allowances] 0 [Inventory] 109,274 [Current-Assets] 143,289 [PP&E] 8,317,394 [Depreciation] (2,788,962) [Total-Assets] 20,942,806 [Current-Liabilities] 655,391 [Bonds] 270,868 [Preferred-Mandatory] 0 [Preferred] 0 [Common] 41,218,293 [Other-Se] (21,185,431) [Total-Liability-And-Equity] 20,942,806 [Sales] 2,511,860 [Total-Revenues] 3,456,418 [Cgs] 578,469 [Total-Costs] 7,160,244 [Other-Expenses] 267,315 [Loss-Provision] 0 [Interest-Expense] 57,355 [Income-Pretax] (4,028,496) [Income-Tax] 0 [Income-Continuing] (4,028,496) [Discontinued] 0 [Extraordinary] 0 [Changes] 0 [Net-Income] (4,028,496) [EPS-Primary] (0.27) [EPS-Diluted] (0.27) </Table>

from 10-Q 1 page [Article] 5 <table> <s> <c> [Period-Type] 6-Mos [Fiscal-Year-End] Jul-31-1998 [Period-End] Jan-31-1998 [Cash] 5,526,986 [Securities] 10,018,440 [Receivables] 429,228 [Allowances] 0 [Inventory] 128,168 [Current-Assets] 113,394 [PP&E] 8,331,682 [Depreciation] (2,529,094) [Total-Assets] 22,368,877 [Current-Liabilities] 654,502 [Bonds] 853,661 [Preferred-Mandatory] 0 [Preferred] 0 [Common] 40,689,312 [Other-Se] (19,717,828) [Total-Liability-And-Equity] 22,368,877 [Sales] 1,311,819 [Total-Revenues] 1,311,819 [Cgs] 4,241,857 [Total-Costs] 4,241,857 [Other-Expenses] (413,389) [Loss-Provision] 0 [Interest-Expense] 44,244 [Income-Pretax] (2,560,893) [Income-Tax] 0 [Income-Continuing] (2,560,893) [Discontinued] 0 [Extraordinary] 0 [Changes] 0 [Net-Income] (2,560,893) [EPS-Primary] (0.17) [EPS-Diluted] (0.17) </Table>

from S-3/A 1 page Underwriting agreement

from S-3 1 page Exhibit 5.1 July 25, 1997 Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, California 92008 Ladies and Gentlemen: You Have Requested Our Opinion With Respect to Certain Matters in Connection With the Filing by Cypros Pharmaceutical Corporation (The "Company") of a Registration Statement on Form S-3 (The "Registration Statement") With the Securities and Exchange Commission Covering the Offer and Sale of Up to an Aggregate of 623,830 Shares of the Company's Common Stock, No Par Value, by a Certain Shareholder, in Connection With the Resale of 623,830 Shares of the Company's Common Stock (The "Converted Shares") Issuable Upon Conversion of a Convertible Note, Due and Payable as of July 9, 1999 (The "Note"). in Connection With This Opinion, We Have Examined the Registration Statement and Related Prospectus, Your Restated Articles of Incorporation, as Amended, Your Bylaws, as Amended, the Note, and Such Other Documents, Records, Certificates, Memoranda and Other Instruments as We Deem Necessary as a Basis for This Opinion. We Have Assumed the Genuineness and Authenticity of All Documents Submitted to US as Originals, the Conformity to Originals of All Documents Submitted to US as Copies Thereof, and the Due Execution and Delivery of All Documents Where Due Execution and Delivery Are a Prerequisite to the Effectiveness Thereof. on the Basis of the Foregoing, and in Reliance Thereon, We Are of the Opinion That the Converted Shares, When Sold and Issued in Accordance With the Note, Will Be Validly Issued, Fully Paid, and Nonassessable. We Consent to the Reference to Our Firm Under the Caption "Legal Matters" in the Prospectus Included in the Registration Statement and to the Filing of This Opinion as an Exhibit to the Registration Statement. Very Truly Yours, Cooley Godward Llp By:/S/ M. Wainwright Fishburn, Jr. - Wainwright Fishburn, Jr

from S-3 1 page Underwriting agreement

from S-3 1 page Underwriting agreement

from S-3 1 page Underwriting agreement

from S-3 1 page Underwriting agreement